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NEUTRON BRACHYTHERAPY
SIR,-We note with interest the results of Professor Maruyama
and colleagues (May 18, p 1120) in advanced carcinoma of the cervix
but do not consider that they represent an advance on existing
techniques. We have achieved a five-year survival of 38% in stage III
carcinoma of the cervix with predominantly external beam
radiotherapy. Others have described similar results.2,3 The 80%
local relapse rate in Maruyama’s historical controls reflected in
their very poor five year survival of only 12% in stage III disease.
The dose to the pelvic side-wall was not standardised and additional
caesium and californium implants were used, so the data provided
do not allow us to compare the two groups. The principal advantage
of intracavity treatment is the very rapid fall-off of dose by an
inverse square law. The technique makes only a modest
contribution to dose at the pelvic side-wall. Since about 38% of
patients with stage III carcinoma of the cervix will have spread of
disease outside the pelvis at presentation,4 long-term survival is
unlikely to be further improved by alterations in local radiotherapy
technique.
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SIR,-The notion that hypoxic but potentially clonogenic cells are
a major cause of local treatment failure in radiotherapy has been
current for nearly 30 years. However, diligent efforts have failed to
reveal significant benefit in advanced cervical cancer from either
treatment in hyperbaric oxygen or treatment in the presence of
selective hypoxic cell radiosensitisers.2 Professor Maruyama and
colleagues (May 18, p 1120) report yet another strategy designed to
overcome the alleged problem of hypoxia in advanced cervical
cancer-namely, the use of densely ionising neutron particles
derived from the radioisotope californium-252. 5-year survival in
stage IIIB carcinoma of the cervix was 54% in patients treated with
californium and external pelvic irradiation (in that order), and 12%
for patients treated with identical pelvic irradiation and subsequent
intracavitary irradiation by caesium-137. The validity of these
results is doubtful:
(1) In this trial, which was not a randomised study, the number of
patients with stage IIIB disease allocated to early californium
brachytherapy or to conventional caesium brachytherapy is small
(42).
(2) The 12% 5-year survival for the "control" arm of the trial
would be regarded as very poor in most major radiotherapeutic
institutions.
(3) 50% of stage IIIB patients had distant metastases, but a 54%
5-year-survival rate is claimed. Are Maruyama et al claiming to cure
every case of stage IIIB cervical cancer that has not already
undergone distant metastasis?
Most cervical cancers reduce in size during external pelvic
irradiation and some degree of re-oxygenation is believed to occur
during such irradiation.3 Consequently, the absolute numbers of
hypoxic cells would be expected to be lowest at the conclusion of
pelvic irradiation and they would be expected to be concentrated
centrally in the pelvis; in this situation they might well prove to be
vulnerable to the poorly penetrating 2 - 3 MEV fast neutrons
emitted by californium. The californium appeared to confer benefit
only when used before pelvic irradiation and not when used
afterwards is an apparent paradox that Maruyama et al make no
attempt to explain.
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CHOLINOMIMETIC DRUG RS 86, REM SLEEP, AND
DEPRESSION
SIR,-Shortening of rapid-eye-movement (REM) sleep latency is
often present in patients with major depressive disorders and is
regarded as a characteristic biological abnormality. In healthy
subjects, infusion of the cholinergic drugs arecholine or
physostigmine during the first non-REM period provokes earlier
onset of REM sleep, suggesting that the spontaneous shortening of
REM latency in depression is a consequence of cholinergic
overactivity. 1 This overactivity, or hypersensitivity of the
cholinergic receptor, has been further illustrated by the effects of
arecholine during the second non-REM period, when the REM-
sleep-provoked effect was significantly more pronounced in
depressive than in healthy subjects. However, when we gave
physostigmine infusions to depressed patients during the first non-
REM/REM cycle, REM latency was not shortened; indeed most
patients woke up.2 2
In the above studies the drugs were given by infusion because of
their short half-lives. Also required, before infusion, was intra-
muscular methscopolamine, a peripheral antidote. The cholinergic
agent RS 86 (Sandoz) offers the opportunity for more convenient
investigation of this issue. RS 86 is an orally acting central
muscarinic agonist with minor peripheral side effects.3 It is a
spirosuccinimide derivative with a half-life of 6-8 h.
In eleven healthy subjects (six females, five males, aged 18-45)
and nine inpatients with a major depressive disorder on Research
Diagnostic Criteria (five females, four males, aged 18-59), we
studied the effect of an oral dose of 1 - 5 mg RS 86 on the first REM
latency. In a double-blind design healthy volunteers randomly
received placebo or 1 - 5 mg RS 86 for one night. Depressed patients
received either placebo or RS 86 for two nights. The drugs and
placebos were taken 1 h before going to sleep. 1 night of adaptation
preceded the study for both healthy and patient volunteers.
1 - 5 mg RS 86 shortened REM latency from 73&plusmn;29 to 61 &plusmn;34 min
in healthy subjects (mean x SD; Wilcoxon test, one-tailed, p<0  05).
This result accords well with Spiegel’s study.3 In depressed
patients, the effect of RS 86 was much more pronounced; REM
latency fell from 56&plusmn;28 to 11 &plusmn;19 min (p<0-005) (see figure).
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The results with RS 86 support the assumption that the
shortening of REM latency in depressives is caused by cholinergic
overactivity, which may be due to a hypersensitivity of cholinergic
receptors. Since RS 86 can be taken by mouth and since there is no
need for a peripheral blocker this compound may have advantages
for multiple testing of the cholinergic involvement in affective
disorders.
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ACUTE POISONING WITH ORPHENADRINE
SiR,-A 40-year-old man with no previous history of epilepsy was
found convulsing in bed. He had a cardiorespiratory arrest in the
ambulance and on arrival in casualty he had a profound bradycardia
(20/min); his blood pressure was unrecordable and he had severe
acidosis. Intubation, ventilation, and cardiac massage were started.
Asystole supervened and huge doses of adrenaline, dopamine, and
dobutamine were needed to achieve a systolic blood pressure of 110 
mm Hg. No tablets were seen on gastric lavage. Because a
neurological cause for the convulsions could not confidently be
excluded, a computerised tomographic head scan and lumbar
puncture were done but were normal.
A drug screen revealed orphenadrine at a concentration of 16  2
mg/1 in blood taken on admission (therapeutic range below 0.2 
mg/1). Treatment with cathartics and activated charcoal was started.
Subsequently his wife told us that he was a chronic schizophrenic on
regular intramuscular depot phenothiazines and oral orphenadrine.
He had gone to bed normally the night before admission and she had
woken up to find him convulsing beside her.
24 h later he was alert and without neurological deficit. Inotropic
support was gradually withdrawn but acute renal failure ensued. No
casts were seen in the urine, and myoglobin was not detected in
blood or urine sampled on admission. His total creatine
phosphokinase (CPK) rose to 12 400 IU/l(normaI15-125) but with
an MB-CPK fraction of less than 6%, indicating that signifi-
cant myocardial damage had not occurred. Transient
hyperphosphataemia and hyperuricaemia were observed,
suggesting that rhabdomyolysis might have contributed to the acute
renal failure besides the hypotension. His serum creatinine reached
a peak of 873 mol/1 (normal below 120 mol/1) but with
conservative measures became normal within 10 days. The patient
has since admitted to poisoning himself deliberately but he could
not estimate how many tablets he had taken or tell us exactly when
he had swallowed them.
Orphenadrine is rapidly absorbed.! It is toxic to most organs and
is directly cardiotoxic. Toxicity begins at concentrations in the
circulation of 2 mg/1, and concentrations of 4-8 mg/1 may be fatal.2 2
Blood levels up to 33 mg/1 were reported in one series of purely
orphenadrine-related deaths.3 Between 1977 and 1980 twelve
deaths due to orphenadrine were recorded by the National Poisons
Unit at Guy’s Hospital (Dr M. Boland, personal communication).
In the three cases of pure orphenadrine poisoning where blood
levels were measured post mortem they were 7, 9, and 18 mg/1,
which suggests that the survival of the patient described here was
remarkable.
Many doctors are unaware of the dangers of orphenadrine in
overdose.4 Treatment with orphenadrine may carry a greater risk
than the drugs whose side-effects it is deemed to control. Up to 50%
of patients on neuroleptic drugs are also given prophylactic
anticholinergic agents.5 Yet in up to 80% of them extrapyramidal
symptoms do not recur when anticholinergic drugs are withdrawn. S
Drugs such as orphenadrine should be prescribed carefully and only
in small amounts to patients in whom it is considered that there is a
real risk of self-poisoning.
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EPIDEMIOLOGY FOR CLINICIANS
SIR,-Your June 1 editorial (p 1256) states that clinicians can
update their knowledge of epidemiology only by attending one-
week courses in Southampton and, now, Edinburgh. Besides our
longer courses we have three-week intensive summer courses in
epidemiology.
London School of Hygiene
and Tropical Medicine,
London WC1E 7HT GEOFFREY ROSE
DURATION OF CYTOSTATIC THERAPY
SIR,-Sir Stanley Peart (May 4, p 1045) describes a case of
reticulum cell sarcoma in which the cessation of cyclophosphamide
after 11 years may have precipitated a fatal relapse. There is no
agreement on the length of cytostatic therapy in malignant diseases.
In bronchial carcinoma the question does not usually arise because
of the brevity of survival in patients with non-operable disease.
However, I have seen a case of lung cancer, resembling Peart’s case,
which has influenced my views on the length of cytostatic therapy.
In July, 1978, a 58-year-old man came to hospital for repair of an
inguinal hernia. A preoperative chest X-ray revealed atelectasis of
the right upper lobe. Studies of sputum and transthoracic fine
needle biopsy specimens revealed microcellular carcinoma. Two
cycles of vincristine and cyclophosphamide were followed by
radiotherapy. The atelectasis disappeared and a 5 x 4 cm tumour
was then seen in the right hilum on chest X-ray. Because of tumour
progression cytostatic therapy was reintroduced in May, 1979,
and 37 cycles were given over the next 41/2 years, during which the
patient’s condition and the size of his tumour remained stable.
In August, 1983, cytostatic therapy was stopped because of
eczema and the attainment of 5 years’ survival. 7 months later
progression of the tumour was seen. Cytostatic therapy with
vincristine and cyclophosphamide was restarted, but the response
was poor. The tumour continued to grow’ slowly. Palliative
radiotherapy had only a limited effect and cisplatin and etoposide
were ineffective. Metastasis to the brain was treated with
radiotherapy in January, 1985. The patient died in April, almost 7
years after presentation.
As in Peart’s case it is difficult to believe that stopping cytostatic
therapy did not precipitate the relapse. This case, climcal
experience, and the experience of Merlier and Le Brigand’ that
after resection of bronchial carcinoma relapses or new growth are
common even after 10 years and that excess mortality due to cancer
is significant up to 15 years indicate that cytostatic therapy in cases
of complete and partial response or stable disease should be
continued for as long as possible and be stopped only because of
severe side-effects or when the maximum safe total dose of a drug
(eg, doxorubicin) has been reached.
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